These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33480648)

  • 1. Management of Hyperhemolysis in β-thalassemia With Multiple Immunosuppressives, Including Complement Blockade.
    Zanetti RC; Vasta LM; Romanelli K; Newton TC
    J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1145-e1147. PubMed ID: 33480648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab.
    Gupta S; Fenves A; Nance ST; Sykes DB; Dzik WS
    Transfusion; 2015 Mar; 55(3):623-8. PubMed ID: 25257194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
    Kulasekararaj AG; Hill A; Rottinghaus ST; Langemeijer S; Wells R; Gonzalez-Fernandez FA; Gaya A; Lee JW; Gutierrez EO; Piatek CI; Szer J; Risitano A; Nakao S; Bachman E; Shafner L; Damokosh AI; Ortiz S; Röth A; Peffault de Latour R
    Blood; 2019 Feb; 133(6):540-549. PubMed ID: 30510079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eculizumab for management of hyperhemolysis syndrome in pediatric patients with sickle cell disease: A single-center case series.
    Lapite A; Bhar S; Fasipe T
    Pediatr Blood Cancer; 2024 Aug; 71(8):e31061. PubMed ID: 38840429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition.
    Vlachaki E; Gavriilaki E; Kafantari K; Adamidou D; Tsitsikas D; Chasapopoulou E; Anagnostopoulos A; Tsapas A
    Hemoglobin; 2018; 42(5-6):339-341. PubMed ID: 30626228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperhaemolytic transfusion reaction in two β-thalassaemia major patients: The role of eculizumab.
    Pantelidou D; Pilalas D; Daios S; Polychronopoulos G; Papadopoulou D; Perifanis V; Savopoulos C; Kaiafa G
    J Clin Pharm Ther; 2022 Mar; 47(3):411-414. PubMed ID: 34397109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.
    Lee JW; Sicre de Fontbrune F; Wong Lee Lee L; Pessoa V; Gualandro S; Füreder W; Ptushkin V; Rottinghaus ST; Volles L; Shafner L; Aguzzi R; Pradhan R; Schrezenmeier H; Hill A
    Blood; 2019 Feb; 133(6):530-539. PubMed ID: 30510080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
    Tomazos I; Sierra JR; Johnston KM; Cheung A; Brodsky RA; Weitz IC
    Hematology; 2020 Dec; 25(1):327-334. PubMed ID: 32856539
    [No Abstract]   [Full Text] [Related]  

  • 9. Approaching treatment of transplant-associated thrombotic Microangiopathy from two directions with Eculizumab and transitioning from Tacrolimus to Sirolimus.
    Jan AS; Hosing C; Aung F; Yeh J
    Transfusion; 2019 Nov; 59(11):3519-3524. PubMed ID: 31587288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.
    Kulasekararaj AG; Hill A; Langemeijer S; Wells R; González Fernández FA; Gaya A; Ojeda Gutierrez E; Piatek CI; Mitchell L; Usuki K; Bosi A; Brodsky RA; Ogawa M; Yu J; Ortiz S; Röth A; Lee JW; Peffault de Latour R
    Eur J Haematol; 2021 Mar; 106(3):389-397. PubMed ID: 33301613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-N and anti-Do
    Unnikrishnan A; Pelletier JPR; Bari S; Zumberg M; Shahmohamadi A; Spiess BD; Michael MJ; Harris N; Harrell D; Mandernach MW
    Transfusion; 2019 Jun; 59(6):1907-1910. PubMed ID: 30768787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
    Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
    Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of Complement in Post-Transfusion Hemolysis and Hyperhemolysis Reaction.
    Roumenina LT; Bartolucci P; Pirenne F
    Transfus Med Rev; 2019 Oct; 33(4):225-230. PubMed ID: 31672341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of immunosuppressive therapy in a patient with aplastic anemia-paroxysmal nocturnal hemoglobinuria (AA-PNH) syndrome during ongoing eculizumab treatment.
    Asano J; Ueda R; Tanaka Y; Shinzato I; Takafuta T
    Intern Med; 2014; 53(2):125-8. PubMed ID: 24429452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Muus P; Szer J; Hill A; Höchsmann B; Kulasekararaj A; Risitano AM; Van Den Neste E; Liljeholm M; Ebrahim KS; Bedrosian CL; Gao X; Ames D; Socié G
    Am J Hematol; 2016 Mar; 91(3):E16-7. PubMed ID: 26690023
    [No Abstract]   [Full Text] [Related]  

  • 16. Delayed hemolytic transfusion reaction with hyperhemolysis after first red blood cell transfusion in child with beta-thalassemia: challenges in treatment.
    Hannema SE; Brand A; van Meurs A; Smiers FJ
    Transfusion; 2010 Feb; 50(2):429-32. PubMed ID: 19788508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed Severe Hemolytic Transfusion Reaction During Pregnancy in a Woman with β-Thalassemia Intermediate: Successful Outcome After Eculizumab Administration.
    Cannas G; Dubreuil L; Fichez A; Gerfaud-Valentin M; Debard AL; Hot A
    Am J Case Rep; 2021 May; 22():e931107. PubMed ID: 33983909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Don't Add Fuel to the Fire"- Hyperhemolysis Syndrome in a Pregnant Woman with Compound Sickle Cell Disease/β0-Thalassemia: Case Report and Review of the Literature.
    Rihsling A; Simeunovic H; Sanchez S; Henny C; Lejon Crottet S; Mansouri Teleghani B; Daskalakis M; Müller M; Raio L; Rovó A
    Acta Haematol; 2024; 147(3):378-387. PubMed ID: 37839398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperhemolysis syndrome complicating pregnancy in homozygous δβ-thalassemia.
    Mechery J; Abidogun K; Crosfill F; Jip J
    Hemoglobin; 2012; 36(2):183-5. PubMed ID: 22239462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective eculizumab therapy followed by BMT in a boy with paroxysmal nocturnal hemoglobinuria.
    Oshiro H; Goi K; Akahane K; Inukai T; Sugita K
    Pediatr Int; 2015 Apr; 57(2):e27-9. PubMed ID: 25868955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.